Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective

Overview

Journal Cardiovasc Drugs Ther

Specialties Cardiology & Vascular Diseases
Pharmacology

Date 2020 Jul 17

PMID 32671601

Citations 25

Authors

Azita Hajhossein Talasaz

Hessam Kakavand

Benjamin Van Tassell

Maryam Aghakouchakzadeh

Parham Sadeghipour

Steven Dunn

Babak Geraiely

Affiliations

Soon will be listed here.

Abstract

Coronavirus disease of 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly the world over. The disease was declared "pandemic" by the World Health Organization. An approved therapy for patients with COVID-19 has yet to emerge; however, there are some medications used in the treatment of SARS-CoV-2 infection globally including hydroxychloroquine, remdesivir, dexamethasone, protease inhibitors, and anti-inflammatory agents. Patients with underlying cardiovascular disease are at increased risk of mortality and morbidity from COVID-19. Moreover, patients with chronic stable states and even otherwise healthy individuals might sustain acute cardiovascular problems due to COVID-19 infection. This article seeks to review the latest evidence with a view to explaining possible pharmacotherapies for the cardiovascular complications of COVID-19 including acute coronary syndrome, heart failure, myocarditis, arrhythmias, and venous thromboembolism, as well as possible interactions between these medications and those currently administered (or under evaluation) in the treatment of COVID-19.

Citing Articles

Coronary Implications of COVID-19.

Triantafyllis A, Sfantou D, Karapedi E, Peteinaki K, Kotoulas S, Saad R Med Princ Pract. 2024; 34(1):1-12.

PMID: 39307131 PMC: 11805551. DOI: 10.1159/000541553.

The Long-Term Cardiovascular Impact of COVID-19: Pathophysiology, Clinical Manifestations, and Management.

Mukkawar R, Reddy H, Rathod N, Kumar S, Acharya S Cureus. 2024; 16(8):e66554.

PMID: 39258051 PMC: 11384648. DOI: 10.7759/cureus.66554.

The Role of Heparin in Postural Orthostatic Tachycardia Syndrome and Other Post-Acute Sequelae of COVID-19.

Gomez-Moyano E, Pavon-Moron J, Rodriguez-Capitan J, Bardan-Rebollar D, Ramos-Carrera T, Villalobos-Sanchez A J Clin Med. 2024; 13(8).

PMID: 38673677 PMC: 11050777. DOI: 10.3390/jcm13082405.

Gold single atom-based aptananozyme as an ultrasensitive and selective colorimetric probe for detection of thrombin and C-reactive protein.

Ali G, Algethami F, Omer K Mikrochim Acta. 2023; 191(1):59.

PMID: 38153560 DOI: 10.1007/s00604-023-06147-6.

QTc Prolongation to Predict Mortality in Patients Admitted with COVID-19 Infection: An Observational Study.

Sartorio A, Burrei G, Cristin L, Zoncape M, Carlin M, Tadiello E Curr Vasc Pharmacol. 2023; 22(2):106-121.

PMID: 38073101 DOI: 10.2174/0115701611250248231114114557.

References

Alhazzani W, Moller M, Arabi Y, Loeb M, Gong M, Fan E . Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020; 46(5):854-887. PMC: 7101866. DOI: 10.1007/s00134-020-06022-5. View

Sapp J, Alqarawi W, MacIntyre C, Tadros R, Steinberg C, Roberts J . Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society. Can J Cardiol. 2020; 36(6):948-951. PMC: 7195336. DOI: 10.1016/j.cjca.2020.04.003. View

Deftereos S, Giannopoulos G, Vrachatis D, Siasos G, Giotaki S, Gargalianos P . Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. JAMA Netw Open. 2020; 3(6):e2013136. PMC: 7315286. DOI: 10.1001/jamanetworkopen.2020.13136. View

Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W . Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020; 382(17):e38. PMC: 7161262. DOI: 10.1056/NEJMc2007575. View

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A . Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020; 382(24):2327-2336. PMC: 7169476. DOI: 10.1056/NEJMoa2007016. View

Grundy S, Stone N, Bailey A, Beam C, Birtcher K, Blumenthal R . 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018; 73(24):3168-3209. DOI: 10.1016/j.jacc.2018.11.002. View

Iba T, Levy J, Warkentin T, Thachil J, van der Poll T, Levi M . Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019; 17(11):1989-1994. DOI: 10.1111/jth.14578. View

Inciardi R, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D . Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020; 5(7):819-824. PMC: 7364333. DOI: 10.1001/jamacardio.2020.1096. View

Raizada M, Ferreira A . ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol. 2007; 50(2):112-9. DOI: 10.1097/FJC.0b013e3180986219. View

10.

Bikdeli B, Madhavan M, Gupta A, Jimenez D, Burton J, Nigoghossian C . Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thromb Haemost. 2020; 120(7):1004-1024. PMC: 7516364. DOI: 10.1055/s-0040-1713152. View

11.

Zaim S, Chong J, Sankaranarayanan V, Harky A . COVID-19 and Multiorgan Response. Curr Probl Cardiol. 2020; 45(8):100618. PMC: 7187881. DOI: 10.1016/j.cpcardiol.2020.100618. View

12.

Ebinger J, Shah P . Declining Admissions for Acute Cardiovascular Illness: The COVID-19 Paradox. J Am Coll Cardiol. 2020; 76(3):289-291. PMC: 7250547. DOI: 10.1016/j.jacc.2020.05.039. View

13.

Reynolds H, Adhikari S, Pulgarin C, Troxel A, Iturrate E, Johnson S . Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med. 2020; 382(25):2441-2448. PMC: 7206932. DOI: 10.1056/NEJMoa2008975. View

14.

Lippi G, Lavie C, Sanchis-Gomar F . Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis. 2020; 63(3):390-391. PMC: 7127395. DOI: 10.1016/j.pcad.2020.03.001. View

15.

Xiong T, Redwood S, Prendergast B, Chen M . Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020; 41(19):1798-1800. PMC: 7454513. DOI: 10.1093/eurheartj/ehaa231. View

16.

Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart D . Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. N Engl J Med. 2020; 383(3):288-290. PMC: 7217555. DOI: 10.1056/NEJMc2013656. View

17.

Chen L, Li X, Chen M, Feng Y, Xiong C . The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020; 116(6):1097-1100. PMC: 7184507. DOI: 10.1093/cvr/cvaa078. View

18.

Roden D, Harrington R, Poppas A, Russo A . Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment. Circulation. 2020; 141(24):e906-e907. DOI: 10.1161/CIRCULATIONAHA.120.047521. View

19.

Haugaa K, Bos J, Tarrell R, Morlan B, Caraballo P, Ackerman M . Institution-wide QT alert system identifies patients with a high risk of mortality. Mayo Clin Proc. 2013; 88(4):315-25. DOI: 10.1016/j.mayocp.2013.01.013. View

20.

Lippi G, Plebani M, Henry B . Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta. 2020; 506:145-148. PMC: 7102663. DOI: 10.1016/j.cca.2020.03.022. View